Latest News

It's been a good week for Vecima Networks Inc. ( TSE:VCM ) shareholders, because the company has just released its...

Gold.com, Inc. ( NYSE:GOLD ) stock is about to trade ex-dividend in four days. The ex-dividend date is one business day...

TMX Group Limited ( TSE:X ) is about to trade ex-dividend in the next 4 days. The ex-dividend date is one business day...

As you might know, Sensus Healthcare, Inc. ( NASDAQ:SRTS ) last week released its latest annual, and things did not...

To the annoyance of some shareholders, Sabre Corporation ( NASDAQ:SABR ) shares are down a considerable 26% in the last...

The Creative Global Technology Holdings Limited ( NASDAQ:CGTL ) share price has softened a substantial 39% over the...

Alliance Entertainment Holding Corporation ( NASDAQ:AENT ) shares have had a horrible month, losing 29% after a...

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...

1-800-FLOWERS.COM, Inc. ( NASDAQ:FLWS ) shares have retraced a considerable 25% in the last month, reversing a fair...

Anaergia Inc. ( TSE:ANRG ) shares have had a horrible month, losing 29% after a relatively good period beforehand...

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

Elutia Inc. ( NASDAQ:ELUT ) shares have continued their recent momentum with a 28% gain in the last month alone. But...

The recent price decline of 15% in Cosmos Health Inc.'s ( NASDAQ:COSM ) stock may have disappointed insiders who bought...

Volatus Aerospace Inc. ( CVE:FLT ) shareholders won't be pleased to see that the share price has had a very rough...

To the annoyance of some shareholders, Cosmos Health Inc. ( NASDAQ:COSM ) shares are down a considerable 27% in the...

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...

Investors may wish to note that the CEO, President & Director of Sagimet Biosciences Inc. , David Happel, recently...

SouthGobi Resources Ltd. ( CVE:SGQ ) shares have had a horrible month, losing 31% after a relatively good period...

When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 19x, you may...

SLB (SLB) has secured multiple offshore drilling and well services contracts from Mubadala Energy for the Tangkulo deepwater natural gas project in Indonesia, highlighting the company’s offshore technologies and integrated model for investors. See our latest analysis for SLB. These new offshore awards arrive after a string of contract wins and technology partnerships. The share price reflects that momentum, with a 30 day share price return of 7.83% and a 90 day share price return of 40.75%,...

Phillips 66 recently reported fourth-quarter 2025 revenue of US$36,333 million and net income of US$2,906 million, and the board has approved a quarterly dividend of US$1.27 per share, payable on March 4, 2026, to shareholders of record on February 23, 2026. The combination of markedly higher quarterly earnings and a 5.8% dividend increase underscores how the company is using improved performance and portfolio changes to support shareholder payouts. We'll now examine how Phillips 66's...

Why Ridgepost Capital Is On Investors’ Radar Ridgepost Capital (RPC) recently rebranded from P10, Inc. This shift is putting fresh attention on how this multi asset class private market solutions provider is positioned across private equity, venture capital, impact investing, and private credit. See our latest analysis for Ridgepost Capital. At a latest share price of $8.70, Ridgepost Capital has seen a 2.35% 1 day share price return. Its 30 day share price return of 18.77% and 1 year total...

In February 2026, NovoCure announced that the U.S. FDA approved Optune Pax for adult patients with locally advanced pancreatic cancer, to be used alongside gemcitabine and nab-paclitaxel after the Phase 3 PANOVA-3 trial showed a statistically significant overall survival benefit without adding meaningful systemic side effects. This approval marks the first new treatment option for locally advanced pancreatic cancer in decades and further validates NovoCure’s Tumor Treating Fields technology...

Why Kao (TSE:4452) is back on investors' radar Kao (TSE:4452) has drawn fresh attention after a packed February 5 update that combined full year 2025 results, new 2026 guidance, a planned share split with higher authorized share capital, and updated dividend plans. See our latest analysis for Kao. At a share price of ¥6,760, Kao has seen a 7.87% 1 month share price return and an 8.07% year to date share price return. Its 3 year total shareholder return of 43.33% suggests momentum has been...